1 – 14 of 14
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
High CYP27A1 expression is a biomarker of favorable prognosis in premenopausal patients with estrogen receptor positive primary breast cancer
(
- Contribution to journal › Article
- 2020
-
Mark
Statin use, HMGCR expression, and breast cancer survival – The Malmö Diet and Cancer Study
(
- Contribution to journal › Article
-
Mark
The effect of statin treatment on intratumoral cholesterol levels and LDL receptor expression : a window-of-opportunity breast cancer trial
(
- Contribution to journal › Article
- 2017
-
Mark
Androgen receptor expression and breast cancer mortality in a population-based prospective cohort
(
- Contribution to journal › Article
-
Mark
Impact of 27-hydroxylase (CYP27A1) and 27-hydroxycholesterol in breast cancer
(
- Contribution to journal › Article
- 2015
-
Mark
Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article
-
Mark
Global transcriptional changes following statin treatment in breast cancer.
(
- Contribution to journal › Article
- 2014
-
Mark
A novel model for Ki67 assessment in breast cancer.
(
- Contribution to journal › Article
-
Mark
71p * statin-induced anti-proliferative effects via cyclin d1 and p27 in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Published meeting abstract
-
Mark
Abstract P2-10-28: The Prognostic Index, KiGE, Combining Proliferation, Histological Grade and Estrogen Receptor Status Challenges Gene Profiling – A Study in 1,854 Chemo-Naïve Women with N0/N1 Primary Breast Cancer.
(
- Contribution to journal › Published meeting abstract
- 2013
-
Mark
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
(
- Contribution to journal › Article
-
Mark
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer.
(
- Contribution to journal › Article
- 2011
-
Mark
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies
(
- Contribution to journal › Article
- 2010
-
Mark
Ki67 proliferation as a biomarker in neo-adjuvant breast cancer studies - core biopsy versus surgical sample
(
- Contribution to journal › Published meeting abstract